[Clinical effectiveness and specific action of antiaggregants in patients with unstable angina].
An open randomized trial was performed of tiklid versus aspirin in patients with unstable angina pectoris (UAP). Tiklid was given to 28 and aspirin to 26 UAP patients. Hemostasis, platelet aggregation, antithrombogenic activity of the vascular wall were studied on the treatment day 1, 20, month 2 and 3. Clinical response was assessed also by the number of anginal attacks, dose of nitroglycerin, data of Holter ECG monitoring. Clinical effect of tiklid appeared higher than that of aspirin. 20-day treatment with tiklid produced a more pronounced decrease in platelet aggregation, and increase in blood and vascular wall anticoagulant potential as well as more potent fibrinolytic effect. These effects persisted for all the observation period. Thus, tiklid in UAP is more advantageous than aspirin because it has more potent antiaggregation action and corrects antithrombogenic properties of the vascular wall.
Rebrov
A P
AP
Voskoboĭ
I V
IV
D000789:Angina, Unstable / Q000097:blood / Q000188:drug therapy*; D001241:Aspirin / Q000627:therapeutic use*; D015716:Electrocardiography, Ambulatory; D005260:Female; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D013988:Ticlopidine / Q000627:therapeutic use*; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine; D001241:Aspirin